Related Experiment Video
Updated: Jul 5, 2026
Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
Published on: September 1, 2023
Safety of MF59 adjuvant
Viola Schultze1, Vicente D'Agosto, Andreas Wack
1Novartis Vaccines and Diagnostics, Marburg, Germany. viola.schultze@novartis.com
MF59 adjuvant emulsion enhances vaccine immunogenicity. Extensive animal and human studies confirm MF59
Area of Science:
- Immunology
- Vaccinology
- Adjuvant development
Background:
- Purified subunit antigens often require adjuvants to boost immune responses.
- MF59 is an oil-in-water emulsion adjuvant developed to enhance antigen immunogenicity.
Purpose of the Study:
- To review the characteristics of the MF59 adjuvant.
- To summarize preclinical and clinical data on MF59.
- To assess the safety of MF59 in human vaccines.
Main Methods:
- Review of animal testing data for MF59.
- Analysis of clinical trial results with MF59-containing vaccines.
- Examination of postmarketing surveillance data for MF59.
Main Results:
- MF59 has demonstrated efficacy in enhancing immune responses in animal models.
- Clinical evaluations in humans have shown successful outcomes with MF59-adjuvanted vaccines.
- Postmarketing surveillance data indicate a favorable safety profile for MF59.
Conclusions:
- MF59 is a well-characterized and effective adjuvant.
- The available data support the safety of MF59 for human use in various vaccine formulations.
More Related Videos
06:57Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
Published on: May 12, 2023
05:44A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis
Published on: December 9, 2022